{"id":820469,"date":"2025-03-03T08:24:07","date_gmt":"2025-03-03T13:24:07","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/kent-lake-nominates-three-highly-qualified-independent-candidates-for-quanterix-board\/"},"modified":"2025-03-03T08:24:07","modified_gmt":"2025-03-03T13:24:07","slug":"kent-lake-nominates-three-highly-qualified-independent-candidates-for-quanterix-board","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/kent-lake-nominates-three-highly-qualified-independent-candidates-for-quanterix-board\/","title":{"rendered":"Kent Lake Nominates Three Highly Qualified, Independent Candidates for Quanterix Board"},"content":{"rendered":"

<\/p>\n

Kent Lake Nominates Three Highly Qualified, Independent Candidates for Quanterix Board<\/b><\/p>\n

Believes Incumbent Board\u2019s Approval and Ongoing Pursuit of Reckless and Dilutive Proposed Merger with Akoya Biosciences Demonstrates Urgent Need for Refreshment<\/i><\/p>\n

Nominees Would Bring Deep Healthcare and Financial Experience Necessary to Properly Oversee a Standalone Quanterix, Prevent Further Capital Misallocation and Improve Shareholder Value<\/i><\/p>\n

Kent Lake Urges Shareholders to Vote Against Merger with Akoya to Protect the Future Value of Their Investment<\/i><\/p>\n

RINCON, Puerto Rico–(BUSINESS WIRE<\/a>)–
\nKent Lake PR LLC (\u201cKent Lake\u201d), a holder of 6.9% of the outstanding common stock of Quanterix Corporation (\u201cQuanterix\u201d or the \u201cCompany\u201d) (NASDAQ: QTRX), announced today it has nominated three highly qualified, independent candidates for election to the Company\u2019s Board of Directors (the \u201cBoard\u201d) at the 2025 Annual Meeting of Shareholders (the \u201cAnnual Meeting\u201d).<\/p>\n

\nKent Lake issued the following statement:<\/p>\n

\n\u201cWe have never before taken a public activist stance at any of the companies in which we are invested, let alone nominated director candidates. However, as a top five shareholder in Quanterix, we are appalled by the Company\u2019s deeply flawed proposed merger (the \u201cMerger\u201d) with Akoya Biosciences (\u201cAkoya\u201d) (NASDAQ: AKYA) and cannot stand idly by. We previously detailed the issues with the Merger in our February 13th<\/sup> open letter<\/a> to shareholders and will not repeat them here. Suffice it to say that the Merger would massively dilute existing shareholders, introduce unnecessary risks and divert focus from the Company\u2019s core growth opportunity \u2013 and shareholders should not approve it.<\/p>\n

\nAt this point, it is clear that the incumbent Board \u2013 which approved and continues to pursue the Merger \u2013 has failed in its core responsibility to act in the best interests of shareholders and cannot be trusted to oversee the Company going forward. That is why we have nominated an outstanding slate of three independent candidates to bring accountability, financial discipline and industry expertise to the boardroom.<\/p>\n

\nThere is a better path forward for shareholders, and we believe that they should have the chance to elect directors who can help the Company refocus on its promising organic growth opportunities in the research market while focusing on the transformational Alzheimer\u2019s testing opportunity. In our view, substantial value can be unlocked by pursuing such a path.<\/p>\n

\nWe look forward to communicating further with our fellow shareholders in the weeks to come.\u201d<\/p>\n

\nKent Lake\u2019s nominees are:<\/p>\n

Alexander G. Dickinson, PhD<\/b><\/p>\n

Dr. Dickinson is a domain expert in life science tools and diagnostics industries and provides valuable perspective as a key industry leader.<\/i><\/p>\n